ANGPTL8 and metabolic dysfunction-associated steatotic liver disease: Recent studies have demonstrated the upregulation of ANGPTL8 gene expression in various related metabolic disorders including insulin resistance, obesity, DM (type I and II), Metabolic Syndrome, Non Alcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma (HCC) emphasizing its assessment as a potential drug target (Chen et al., 2014; Fu et al., 2014b; Hu et al., 2014, 2017; Yamada et al., 2015; Abu-Farha et al., 2016; Guo et al., 2016; Lee et al., 2016; Yin et al., 2017).